New combo therapy shows promise for rare chest cancer

NCT ID NCT06019468

First seen May 13, 2026 · Last updated May 13, 2026

Summary

This study tests whether combining the drug envolizumab with radiation therapy before surgery can shrink tumors in people with locally advanced thymic carcinoma, a rare chest cancer. About 25 adults aged 18-75 will receive the combination treatment, then have surgery to remove any remaining cancer. The goal is to see if this approach makes surgery more effective and to check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Pulmonary Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.